Reaction

Drug Specific Antibody Present reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 6,402 reports · 92 co-occurring drugs

As of the last recalculation, Drug Specific Antibody Present appears in 6,402 FAERS reports alongside 92 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 82.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Infliximab-Dyyb	665	82.4	84.3
Agalsidase Beta	204	74.1	75.7
Infliximab	1,738	35.1	35.4
Adalimumab-Fkjp	419	31.4	31.7
Adalimumab-Aaty	427	31.4	31.6
Adalimumab-Adaz	424	27.9	28.1
Natalizumab	992	20.8	20.9
Mesalamine	315	19.1	19.2
Anakinra	91	18.1	18.2
Emicizumab	64	17.0	17.1
Azathioprine	379	14.8	14.9
Mercaptopurine	67	12.7	12.7
Adalimumab	1,967	12.6	12.6
Hydrocortisone Sodium Succinate	36	12.5	12.6
Vedolizumab	282	11.1	11.1
Anti-Itch	202	10.1	10.1
Anti-Pruritic	202	10.1	10.1
Antipruritic (Anti-Itch)	202	10.1	10.1
Cool Relief Gel With Aloe	202	10.1	10.1
Drs. Hydrocortisone	202	10.1	10.1
Hydrocortisone Continuous Spray	202	10.1	10.1
Hydrocortisone Spray	202	10.1	10.1
Hydrocortisone Cream	203	10.1	10.1
Anti-Itch Cream	202	10.1	10.1
Hydrocortisone Lotion	202	10.1	10.1
Hydrocortisone Cream 1%	202	10.1	10.1
Hydrocortisone Cream 1/2%	202	10.1	10.1
Hydrocortisone 1%	202	10.1	10.1
Desoximetasone	57	9.8	9.8
Hydrocortisone Acetate	205	9.4	9.5
Hydrocortisone	242	9.1	9.1
Dimenhydrinate	27	8.3	8.3
Diphenhydramine	154	8.1	8.1
Botulinum Toxin Type A	30	7.9	7.9
Budesonide	120	6.7	6.7
Telmisartan	34	6.2	6.2
Diphenhydramine Hydrochloride	302	6.2	6.2
Prednisone	713	5.1	5.1
Golimumab	126	4.9	4.9
Iron	94	4.6	4.6
Ustekinumab	143	4.6	4.6
Cholestyramine	17	4.6	4.6
Methotrexate	536	4.4	4.4
Methylprednisolone Sodium Succinate	61	4.3	4.3
Methotrexate Sodium	578	4.2	4.2
Sumatriptan Succinate	32	4.1	4.1
Tocilizumab	141	4.1	4.1
Obinutuzumab	20	4.0	4.0
Interferon Beta-1A	218	3.8	3.8
Hydroxychloroquine	85	3.7	3.7
Tofacitinib Citrate	15	3.7	3.7
Anti-Thymocyte Globulin (Rabbit)	9	3.6	3.6
Metronidazole	69	3.5	3.5
Interferon Beta-1B	20	3.4	3.4
Sulfasalazine	81	3.4	3.4
Dexlansoprazole	43	3.4	3.4
Romiplostim	15	3.2	3.2
Leflunomide	103	3.2	3.2
Iron Sucrose	9	3.1	3.1
Pantoprazole Sodium In 0.9% Sodium Chloride	58	3.1	3.1
Pantoprazole Sodium Injection	58	3.1	3.1
Dicyclomine Hydrochloride	13	3.0	3.0
Hydroxychloroquine Sulfate	79	2.8	2.8
Hyoscyamine Sulfate	8	2.8	2.8
Ciprofloxacin Hydrochloride And Hydrocortisone	18	2.8	2.8
Rosuvastatin Calcium	24	2.8	2.8
Abatacept	116	2.8	2.8
Triamcinolone Acetonide Ointment Usp, 0.05%	19	2.6	2.6
Metronidazole Topical	38	2.6	2.6
Bupropion	35	2.6	2.6
Calcium	114	2.5	2.5
Isoniazid	12	2.4	2.4
Certolizumab Pegol	86	2.4	2.4
Sumatriptan	28	2.4	2.4
Venlafaxine	50	2.3	2.3
Asfotase Alfa	7	2.3	2.3
Rifaximin	13	2.0	2.0
Fondaparinux Sodium	5	2.0	2.0
Triamcinolone Acetonide	19	2.0	2.0
Pyrazinamide	5	1.7	1.7
Upadacitinib	36	1.4	1.4
Onabotulinumtoxina	31	1.3	1.3
Methoxy Polyethylene Glycol-Epoetin Beta	4	1.2	1.2
Tofacitinib	63	1.1	1.1
Fentanyl Citrate	6	1.1	1.1
Tapentadol Hydrochloride	11	1.1	1.1
Glatiramer Acetate	19	1.0	1.0
Etanercept	187	1.0	1.0
Benralizumab	6	1.0	1.0
Dalfampridine	20	0.9	0.9
Ixekizumab	8	0.7	0.7
Guselkumab	5	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.